Newsletter | February 14, 2024

02.14.24 -- A Future Renaissance At Catalent? Employees Think So

FEATURED EDITORIAL

A Future Renaissance At Catalent? Employees Think So

By Louis Garguilo, chief editor, Outsourced Pharma

Regarding Monday's news of the purchase of Catalent by Novo Holdings, the seminal question we needed a more definitive answer to is: What specifically is planned for Catalent as a CDMO? Chief editor Louis Garguilo got some answers. “Customers have been calling me continuously,” said one Catalent executive he spoke with.

How To Speed Up Time-To-Market With CMC Knowledge Management

By Irwin Hirsh, Q-Specialists AB

Poor knowledge management delays regulatory approval and, thus, market access. Here's the first in a series examining the complexity of knowledge management for CMC and across the value stream.

INDUSTRY INSIGHTS

Making A Case For A Fixed Dose Combination (FDC) Drug Strategy

Article | Pfizer CentreOne

As patient centricity spurs innovation in drug delivery systems, examine the potential of FDCs to provide convenient dosing and how increased patient compliance is alleviating the cost of healthcare.

Components Of An Effective Disinfectant Prequalification Strategy

White Paper | By Mariana Breña, Christopher Parker, and Michael Mrvos, Cambrex

Cleaning procedures designed specifically to destroy microbial contaminants that may be present are an important component of any microbial control strategy.

Liquid-Filled Hard-Shell Capsules In Drug Development Applications

e-book | Altasciences

Explore the versatility and significance of LFHCs in pharmaceutical delivery, as well as their role in enhancing drug solubility, bioavailability, and overall efficiency.

The Power Of AI And Route Scouting To Navigate API Complexity

Q&A | Lonza

Using AI tools for retrosynthesis can help you investigate molecules interactively to build a complex API manufacturing process that maintains your timeline and saves you money.

Choosing A Formulation And Process Approach To OCR Products

White Paper | By Richard Sidwell, Ph.D., Societal CDMO

Do you want to develop an oral controlled release (OCR) product? Understand the options and their ramifications as the first step toward devising a plan.

SPONSOR

SOLUTIONS

Commercial Drug Sourcing For Clinical Trials

Catalent

Learn how the right partner can leverage years of experience, market knowledge, industry relationships, and clinical packaging expertise to develop a sourcing strategy tailored to the needs of each study.

How Can Nanoparticle Engineering Make The Difference For Alzheimer’s?

Nanoform

Commercial insights officer Jamie Unwin discusses the power of an innovative nanoparticle engineering technology and its AI-based digital twin.

OUTSOURCED PHARMA CAPACITY UPDATE

Find Your New CDMO At Outsourced Pharma Capacity Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: